Analysts Set Qiagen N.V. (NYSE:QGEN) Price Target at $55.20

Qiagen N.V. (NYSE:QGEN) has received a consensus rating of “Hold” from the twelve brokerages that are presently covering the company, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $55.1988.

A number of research firms have recently weighed in on QGEN. UBS Group set a $52.00 target price on shares of Qiagen in a research report on Monday, February 9th. Robert W. Baird set a $53.00 price objective on Qiagen in a report on Friday, February 6th. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a research note on Monday, December 29th. Wall Street Zen cut Qiagen from a “buy” rating to a “hold” rating in a research report on Saturday, January 10th. Finally, Stifel Nicolaus set a $50.00 price objective on Qiagen and gave the stock a “hold” rating in a report on Friday, February 6th.

Institutional Trading of Qiagen

Several hedge funds and other institutional investors have recently modified their holdings of QGEN. Danske Bank A S purchased a new position in Qiagen in the 3rd quarter valued at approximately $36,000. Smartleaf Asset Management LLC lifted its position in shares of Qiagen by 1,383.3% during the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after acquiring an additional 830 shares in the last quarter. Manchester Capital Management LLC bought a new position in shares of Qiagen in the fourth quarter worth $42,000. MAI Capital Management grew its position in shares of Qiagen by 998.9% in the second quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after purchasing an additional 889 shares in the last quarter. Finally, Global Retirement Partners LLC grew its position in shares of Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after purchasing an additional 851 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Down 0.8%

Shares of NYSE:QGEN opened at $50.45 on Friday. Qiagen has a 1 year low of $39.61 and a 1 year high of $57.81. The company has a market capitalization of $10.65 billion, a PE ratio of 25.02, a price-to-earnings-growth ratio of 2.46 and a beta of 0.67. The business has a fifty day moving average price of $49.78 and a two-hundred day moving average price of $49.53. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.90 and a quick ratio of 3.31.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Thursday, February 5th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. The company had revenue of $540.42 million for the quarter, compared to the consensus estimate of $528.53 million. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.61 EPS. Analysts forecast that Qiagen will post 2.26 earnings per share for the current year.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.